Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Chin J Integr Med. 2022 Aug;28(8):762-768. doi: 10.1007/s11655-020-3254-9. Epub 2020 Mar 7.
Qinghuang Powder (QHP), an oral arsenic, has become an effective drug in the treatment of myelodysplastic syndromes (MDS) in Xiyuan Hospital, China Academy of Chinese Medical Sciences for many years, and the action mechanism of the compound or active ingredient AsS of QHP has been elucidated. Considering the relatively safety, chemotherapy-free and convenient oral profile, QHP is widely used in the clinical treatment for MDS patients, especially for elderly patients. In this review, the authors document the efficacy and safety of oral arsenic-containing compound QHP in the treatment of MDS, with a special focus on the association of efficacy of QHP with the cytogenetics, prognostic risk, DNA methylation, gene mutation, blood arsenic concentration, mechanism of action of AsS and the countermeasures against adverse reactions of gastrointestinal tract.
青黄散（QHP）是一种口服砷剂，多年来已成为中国中医科学院西苑医院治疗骨髓增生异常综合征（MDS）的有效药物，其复方或有效成分 AsS 的作用机制已阐明。鉴于 QHP 相对安全、无需化疗且口服方便的特点，QHP 已广泛应用于 MDS 患者的临床治疗，特别是老年患者。在这篇综述中，作者记录了口服含砷化合物 QHP 治疗 MDS 的疗效和安全性，特别关注 QHP 的疗效与细胞遗传学、预后风险、DNA 甲基化、基因突变、血砷浓度、AsS 作用机制以及胃肠道不良反应对策之间的关系。
